Healthcare
Castle Biosciences Inc(CSTL)
Live Price
Offline$21.20
+0.38% today
1Y Change
+5.08%
Window
Jun 25, 2025 β Jun 16, 2026
- Market Cap
- $750.00M
- Revenue Growth
- +3.7%
- EPS Growth
- -225.8%
- Dividend Yield
- 0.0%
Coverage: 245 bars Β· Jun 25, 2025 β Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Castle Biosciences Inc (CSTL) is a Healthcare stock with a market cap of $750.00M and listed on NASDAQ. The stock last traded around $21.20 and up 5.1% across the available one-year price window (Jun 25, 2025 β Jun 16, 2026). Baseline metrics include revenue growth of +3.7%, EPS growth of -225.8%, a dividend yield of 0.0%. What stands out right now is revenue +3.7%, EPS -225.8%, free cash flow -22.5% with operating margin -12.4% and ROIC -6.8%. Valuation is more restrained than many high-expectation growth names at price/sales 2.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CSTL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+3.7% vs +7.6% peer median
Operating Margin
Below sector median
-12.4% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 4, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +3.7% and EPS is at -225.8%, with operating margin around -12.4%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -1.4% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 4, 2026 | β | -3.6% | -25.4% | -22.8% |
2026 Feb 26, 2026 | +65.2% | -7.2% | -12.5% | -22.5% |
2025 Nov 3, 2025 | +94.1% | +21.7% | +33.7% | +50.4% |
Benchmark Edge
CSTL vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CSTL
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CSTL Max Drawdown
-57.83%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CSTL and SPY.
Company Overview
Castle Biosciences Inc
NASDAQ
Castle Biosciences, Inc. is a molecular diagnostics company that develops and provides innovative gene expression profile tests to guide patient care in oncology and related fields. Its portfolio includes DecisionDx-Melanoma, a risk stratification test predicting metastasis risk in cutaneous melanoma patients; DecisionDx-SCC for assessing recurrence and metastasis risk in cutaneous squamous cell carcinoma; DecisionDx-UM for uveal melanoma metastasis risk; MyPath Melanoma, a diagnostic tool for challenging melanoma cases; and TissueCypher for evaluating progression risk in Barrettβs esophagus patients. These tests support clinical decisions in dermatologic cancers, esophageal conditions, and uveal melanoma by offering personalized risk assessments that inform treatment pathways. Castle Biosciences, Inc. focuses on areas where precise diagnostics can improve outcomes, such as identifying low-risk patients to avoid overtreatment and high-risk individuals for intensified monitoring. Founded in 2008 and headquartered in Friendswood, Texas, the company operates at the intersection of precision medicine and healthcare, delivering tests that enhance decision-making for physicians and patients across these specialized medical domains.
- Leadership
- Mr. Derek J. Maetzold
- Employees
- 883
- Street Address
- 1500 W. Parkwood Ave, Suite 400
- Mailing
- Friendswood, TX, 77546
- Region
- Friendswood, TX, United States
- Last Updated
- May 8, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- β
- EV/EBITDA
- 50.7
- Price/Sales
- 2.2
- Price/Book
- 1.5
Growth
- Revenue
- +3.7%
- EPS
- -225.8%
- Free Cash Flow
- -22.5%
Profitability
- Gross Margin
- 68.7%
- Operating Margin
- -12.4%
- Net Margin
- -7.0%
- ROE
- -5.3%
- ROIC
- -6.8%
Balance Sheet
- Debt/Equity
- 0.08
- Current Ratio
- 5.26
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.